preclinical drug development miss sirikan nawapan
TRANSCRIPT
![Page 1: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/1.jpg)
Preclinical Drug Development
Miss Sirikan Nawapan
![Page 2: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/2.jpg)
Objectives
To evaluate the anticancer properties of this modified drug by studying
cell proliferation tumor volumetric
apoptosis DNA fragment
To provide the evidence for supporting the safety of use in patient treatment
![Page 3: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/3.jpg)
Components of Preclinical Drug Development
1. In vitro study
: Cytotoxicity assay
2. In vivo study
: Pharmacokinetic study
: Animal testing
: Toxicity test
![Page 4: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/4.jpg)
In vitro study
ObjectivesTo study the effectiveness of the drug
on the growth of HepG2 cells and to provide the appropriate concentration using in vivo study.
![Page 5: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/5.jpg)
Components of in vitro study of in vitro study
1. Preparation of HepG2 cells
2. Cytotoxicity test
2.1 Dose dependent inhibition
2.2 Time dependent inhibition
3. Determination of cell cycle and apoptosis
![Page 6: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/6.jpg)
Preparation of HepG2 cells line
cDNAs contain the full-length ER and ER∆5
pcDNA3
Transfect in to HepG2 cells line
Introduce cDNA into pcDNA3
![Page 7: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/7.jpg)
2HepG + ER ∆ 5
2 + ERα
MTT assay
stock solution
conc1
conc4
conc3
conc2
conc5
control
Cytotoxicity test
![Page 8: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/8.jpg)
0
20
40
60
80
100
120
0 200 400 600 800 1000modified megestol concentration (µM)
% Cell su
rviva
l
IC50
Dose dependent inhibition of HepG2 cells by modified megestrol
![Page 9: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/9.jpg)
Time dependent inhibition of HepG2 cells by modified megestrol
0
50
100
150
200
250
300
0 10 20 30 40 50 60Time (hr)
% Orig
inal C
ell No
controlIC 50 of m-megestrol
![Page 10: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/10.jpg)
Cell suspensions and Propidium Iodide Staining
Determination of Cell Cycle and Apoptosis
HepG2 cell lines
Analyzed by Flow cytometry
ApopAlert LM-PCR Ladder Assay kit+
![Page 11: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/11.jpg)
In vivo study
ObjectiveTo study the efficacy and toxicity of the modified drug in nude mice.
Components of in vivo study
1. Pharmacokinetic study
2. Animal testing
3. Toxicity test
![Page 12: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/12.jpg)
Pharmacokinetic study
Control
Male
Female
Blood, Urine, Feces samples
High Performance Liquid Chromatography (HPLC)
14C-Radiolabeled Modified Megestrol
![Page 13: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/13.jpg)
Qualitative Distribution Study
Male Female Pregnant
Sacrificed and Sagittal Section (30m)
Whole Body Autoradiography
![Page 14: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/14.jpg)
Animal testing
HepG2 + vERHepG2 + vERHepG2 + vER
Modified Megestrol
male femalecontrol
Vehicle
![Page 15: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/15.jpg)
Animal Testing Endpoints
Week
Tu
mo
r V
ol (
% O
rig
Vo
l)B
od
y W
eig
ht
(g)
% o
f su
rviv
ors body weight (g) = total weight (g) – tumor volume(cm3)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
![Page 16: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/16.jpg)
Toxicity Test
Test 1:The LD50 determination
5 doses and 6 mices/sex/dose
Test 2:The LD50 determination (finely tune)
5 doses and 6 mices/sex/dose
Test 3:Acute toxicity test
3 dose of test 2 and 6 mices/sex/dose
Test 4:Subchronic toxicity test
1/20 dose of test 2 ,10 mices/sex/dose
Test 5: Chronic toxicity test
No-effect dose in test 4,10 mices/sex/dose
![Page 17: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/17.jpg)
Summary
Tested drug In vitro In vivo Clinical trials
IC50
Phase I staring dose
-Anticancer properties of drug
-Toxicity testing
![Page 18: Preclinical Drug Development Miss Sirikan Nawapan](https://reader036.vdocument.in/reader036/viewer/2022062404/5518c4d8550346a61f8b574b/html5/thumbnails/18.jpg)
THE END